RENVELA

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, South Africa, Spain, UK.

Active ingredients

The drug RENVELA contains one active pharmaceutical ingredient (API):

1	Sevelamer UNII 9YCX42I8IU - SEVELAMER CARBONATE
	Sevelamer is a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium. Sevelamer contains multiple amines separated by one carbon from the polymer backbone which become protonated in the stomach. These protonated amines bind negatively charged ions such as dietary phosphate in the intestine.
	Read more about Sevelamer

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RENVELA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
RENVELA Powder for oral suspension	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V03AE02	Sevelamer	V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia
Discover more medicines within V03AE02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02354586, 02485559, 02485567
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	1405-MEE-0915
EE	Ravimiamet	1422414, 1422425, 1422436, 1422447, 1422458, 1422469, 1780578
ES	Centro de información online de medicamentos de la AEMPS	09521003, 09521007, 109521008
FI	Lääkealan turvallisuus- ja kehittämiskeskus	036062, 036073, 478135
FR	Base de données publique des médicaments	61136926, 63716917, 67392245
GB	Medicines & Healthcare Products Regulatory Agency	181374, 182911, 368724, 375943, 381660, 393546
HK	Department of Health Drug Office	60178
IL	מִשְׂרַד הַבְּרִיאוּת	6690, 6691
IT	Agenzia del Farmaco	039480037, 039480064
LT	Valstybinė vaistų kontrolės tarnyba	1050558, 1050559, 1050560, 1050561, 1050562, 1050563, 1050564, 1086339, 1088300
NL	Z-Index G-Standaard, PRK	207020, 90131, 90158
PL	Rejestru Produktów Leczniczych	100054613, 100075650, 100087854, 100412917
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W54577001, W54577002, W54577003, W54578001, W54578002, W54579001, W54579002
SG	Health Sciences Authority	13725P
US	FDA, National Drug Code	58468-0130, 58468-0131, 58468-0132
ZA	Health Products Regulatory Authority	45/32.16/0305